Skip to search formSkip to main contentSkip to account menu

CDK4/6 Inhibition

Known as: Cyclin-Dependent Kinases 4 and 6 Inhibition 
Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling
SHP2 (PTPN11) is a protein tyrosine phosphatase and scaffold protein that functions as a convergent node downstream of multiple… 
2018
2018
Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition…
2017
2017
Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer
The use of CDK inhibitors (palbociclib, ribociclib, abemaciclib) for patients with metastatic ER-positive breast cancer has been… 
2017
2017
Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with…
Background Cyclin dependent kinase 4/6 inhibitors (CDK4/6i), including palbociclib and ribociclib (R), have demonstrated… 
2017
2017
Abemaciclib Shows Promise for Early Breast Cancer.
Treatment with the CDK4/6 inhibitor abemaciclib, alone or in combination with endocrine therapy, significantly lowered expression… 
2017
2017
Abstract LB-298: The novel triple PI3K-CDK4/6-BRD4 inhibitor SRX3177 harnesses synthetic lethality relationships to orthogonally disrupt cancer cell signaling
Dysregulation of the cell cycle is a hallmark of nearly all cancers, and efforts to target signaling pathways regulating cell… 
2016
2016
CDK4/6 Inhibition Overcomes Drug Resistance in HER2+ Breast Cancer.
Resistance to targeted therapies in HER2(+) breast cancer is mediated by cyclin D1 and CDK4. 
2015
2015
CDKN 2 A / p 16 Loss Implicates CDK 4 as a Therapeutic Target in Imatinib-Resistant Dermato fi brosarcoma Protuberans
Dermatofibrosarcoma protuberans (DFSP) is an aggressive PDGFB-dependent cutaneous sarcoma characterized by infiltrative growth… 
2013
2013
Abstract S4-04: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
Various components of the phosphatidylinositol 3-kinase (PI3K) pathway are deregulated across a spectrum of human cancers… 
2011
2011
Abstract 233: Crosstalk of Her2 signaling and cell cycle control in the response to targeted therapeutics in breast cancer
Previous studies have shown that breast cancer is associated with genetic and molecular modifications, such as aberrant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)